Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,481 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Rise of plasma myeloperoxidase during interferon therapy.
Nakamuta M, Ohashi M, Fukutomi T, Tanabe Y, Hiroshige K, Nawata H. Nakamuta M, et al. Among authors: tanabe y. J Gastroenterol Hepatol. 1995 May-Jun;10(3):277-80. doi: 10.1111/j.1440-1746.1995.tb01093.x. J Gastroenterol Hepatol. 1995. PMID: 7548803 Clinical Trial.
Association between the treatment length and cumulative dose of pegylated interferon alpha-2b plus ribavirin and their effectiveness as a combination treatment for Japanese chronic hepatitis C patients: project of the Kyushu University Liver Disease Study Group.
Furusyo N, Kajiwara E, Takahashi K, Nomura H, Tanabe Y, Masumoto A, Maruyama T, Nakamuta M, Enjoji M, Azuma K, Shimono J, Sakai H, Shimoda S, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group. Furusyo N, et al. Among authors: tanabe y. J Gastroenterol Hepatol. 2008 Jul;23(7 Pt 1):1094-104. doi: 10.1111/j.1440-1746.2008.05319.x. Epub 2008 Feb 3. J Gastroenterol Hepatol. 2008. PMID: 18248381 Clinical Trial.
Evaluation of the adverse effect of premature discontinuation of pegylated interferon α-2b and ribavirin treatment for chronic hepatitis C virus infection: results from Kyushu University Liver Disease Study.
Ogawa E, Furusyo N, Kajiwara E, Takahashi K, Nomura H, Tanabe Y, Satoh T, Maruyama T, Nakamuta M, Kotoh K, Azuma K, Dohmen K, Shimoda S, Hayashi J; Kyushu University Liver Disease Study [KULDS] Group. Ogawa E, et al. Among authors: tanabe y. J Gastroenterol Hepatol. 2012 Jul;27(7):1233-40. doi: 10.1111/j.1440-1746.2011.06965.x. J Gastroenterol Hepatol. 2012. PMID: 22098185 Clinical Trial.
Efficacy and safety of splenectomy in telaprevir-based triple therapy for chronic hepatitis C patients with thrombocytopenia and advanced fibrosis.
Ogawa E, Furusyo N, Nakamuta M, Kajiwara E, Nomura H, Dohmen K, Takahashi K, Satoh T, Azuma K, Kawano A, Tanabe Y, Kotoh K, Shimoda S, Akahoshi T, Maehara Y, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group. Ogawa E, et al. Among authors: tanabe y. J Gastroenterol Hepatol. 2014 Sep;29(9):1728-35. doi: 10.1111/jgh.12619. J Gastroenterol Hepatol. 2014. PMID: 24731162 Clinical Trial.
Oral contraceptive-dependent growth of focal nodular hyperplasia.
Nakamuta M, Ohashi M, Fukutomi T, Tanabe Y, Hiroshige K, Nakashima O, Nawata H. Nakamuta M, et al. Among authors: tanabe y. J Gastroenterol Hepatol. 1994 Sep-Oct;9(5):521-3. doi: 10.1111/j.1440-1746.1994.tb01286.x. J Gastroenterol Hepatol. 1994. PMID: 7827306
1,481 results